BR9810409A - Métodos e composições para a modulação de responsividade a corticosteróides - Google Patents
Métodos e composições para a modulação de responsividade a corticosteróidesInfo
- Publication number
- BR9810409A BR9810409A BR9810409-8A BR9810409A BR9810409A BR 9810409 A BR9810409 A BR 9810409A BR 9810409 A BR9810409 A BR 9810409A BR 9810409 A BR9810409 A BR 9810409A
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- cortecosteroid
- individual
- methods
- preferred
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
US1634698A | 1998-01-30 | 1998-01-30 | |
PCT/US1998/004916 WO1998041232A2 (fr) | 1997-03-18 | 1998-03-12 | Procedes et compositions permettant de moduler la sensibilite aux corticosteroides |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9810409A true BR9810409A (pt) | 2000-08-22 |
Family
ID=26688484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9810409-8A BR9810409A (pt) | 1997-03-18 | 1998-03-12 | Métodos e composições para a modulação de responsividade a corticosteróides |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0998300A1 (fr) |
JP (1) | JP2002504091A (fr) |
KR (1) | KR20000076420A (fr) |
CN (1) | CN1269722A (fr) |
AU (1) | AU734756B2 (fr) |
BG (1) | BG103808A (fr) |
BR (1) | BR9810409A (fr) |
CA (1) | CA2282845A1 (fr) |
DE (1) | DE998300T1 (fr) |
ES (1) | ES2146192T1 (fr) |
HU (1) | HUP0104439A3 (fr) |
ID (1) | ID22975A (fr) |
IL (1) | IL131815A0 (fr) |
NO (1) | NO994506L (fr) |
NZ (1) | NZ337769A (fr) |
PL (1) | PL336464A1 (fr) |
SI (1) | SI20110A (fr) |
SK (1) | SK122199A3 (fr) |
TR (1) | TR199902615T2 (fr) |
WO (1) | WO1998041232A2 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
EP1516630A3 (fr) * | 1997-10-31 | 2006-05-03 | Wyeth | Utilisation d'anticorps anti-il12 pour empêcher le rejet des greffes |
AU744302B2 (en) * | 1997-10-31 | 2002-02-21 | Beth Israel Deaconess Medical Center | Use of anti-IL-12 antibodies in transplantation rejection |
WO1999025737A1 (fr) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions et procedes de traitement de maladies autoimmunes a l'aide d'un anticorps monoclonal se liant a la chaine interleukine-12 beta2 |
KR20010041905A (ko) * | 1998-03-16 | 2001-05-25 | 시토비아 인크. | 디펩티드 카스파제 억제제 및 이의 용도 |
CA2355345A1 (fr) * | 1998-11-27 | 2001-06-28 | Technion Research & Development Foundation Ltd. | Vaccin base sur un facteur d'induction de l'interferon gamma et utilisation de ce vaccin destine a conferer une immunite de protection contre la sclerose multiple |
DE69927520T2 (de) * | 1998-12-09 | 2006-06-22 | Protein Design Labs, Inc., Fremont | Verwendung von il-12 antikörpern zur behandlung von psoriasis |
AU3876600A (en) | 1999-03-16 | 2000-10-04 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DE19915465A1 (de) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten |
KR20020005665A (ko) | 1999-04-09 | 2002-01-17 | 추후보정 | 카스파제 저해제 및 그것의 용도 |
IL131047A0 (en) * | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
MXPA02002038A (es) | 1999-08-27 | 2002-10-31 | Cytovia Inc | Acidos alfa-hidroxi substituidores inhibidores de la caspasa y uso de los mismos. |
WO2001019373A2 (fr) * | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Procedes et compositions permettant de moduler la sensibilite aux corticosteroides |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
HUP0300423A3 (en) | 2000-02-10 | 2008-07-28 | Abbott Lab | Antibodies that bind human interleukin-18 and methods of making and using |
EP1289557B1 (fr) * | 2000-06-06 | 2006-07-12 | Glaxo Group Limited | Composition pour le traitement du cancer comprenant un agent anti-neoplastique et un inhibiteur de pde4 |
WO2001097815A2 (fr) * | 2000-06-22 | 2001-12-27 | Willy Ben Moussa Ben Mohammed | Utilisation de glucocorticosteroides pour la production d'un medicament servant a traiter l'alopecie |
US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
WO2002022127A1 (fr) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal |
EP1199074A1 (fr) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Composition pharmaceutique pour la prévention ou le traitement de maladies associées à un excès de production d' IL-12 |
EP1188438A1 (fr) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Compositions pharmaceutiques pour la prévention ou le traitement de maladies associées à un excès de production de l' IL-12 |
WO2002060479A1 (fr) * | 2001-01-29 | 2002-08-08 | Applied Research Systems Ars Holding N.V. | Utilisation d'inhibiteurs d'il-18 pour le traitement et/ou la prevention de cardiopathies |
SI1425028T1 (sl) * | 2001-05-16 | 2010-02-26 | Yeda Res & Dev | Uporaba inhibitorjev za il-18 za zdravljenje ali prepreäśevanje sepse |
SG173211A1 (en) | 2001-06-26 | 2011-08-29 | Amgen Inc | Antibodies to opgl |
WO2003030823A2 (fr) * | 2001-10-05 | 2003-04-17 | Combinatorx, Incorporated | Combinaisons permettant le traitement des troubles inflammatoires |
JP2003342196A (ja) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | 静脈注射用組成物、その製造法およびその製剤 |
AU2003299196A1 (en) * | 2002-09-24 | 2004-04-23 | Combinatorx, Incorporated | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
WO2004028545A1 (fr) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | Combinaison d'un agoniste $g(b)2 a action prolongee et d'un glucocorticosteroide dans le traitement de maladies fibrotiques |
WO2004067006A1 (fr) * | 2003-01-27 | 2004-08-12 | Pharmacia Corporation | Combinaison d'un inhibiteur de la pde iv et d'un antagoniste du tnf-alpha |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
CA2566877A1 (fr) * | 2004-05-17 | 2005-11-24 | Keio University | Composition medicinale et procede therapeutique |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
NZ553166A (en) * | 2004-07-16 | 2010-02-26 | Atsuo Sekiyama | IL-18 receptor antagonist and pharmaceutical composition containing the antagonist |
CA2584169A1 (fr) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Traitements prophylactiques ou therapeutiques de maladie chronique de la peau |
PL1921919T3 (pl) | 2005-07-14 | 2012-09-28 | Lithera Inc | Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej |
MX2009004198A (es) * | 2006-10-17 | 2009-10-19 | Lithera Inc | Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea. |
KR20150038227A (ko) | 2007-01-16 | 2015-04-08 | 애브비 인코포레이티드 | 건선의 치료방법 |
NZ598881A (en) | 2007-03-29 | 2013-11-29 | Abbvie Inc | Crystalline anti-human il-12 antibodies |
US8178092B2 (en) | 2008-03-18 | 2012-05-15 | Abbott Laboratories | Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23 |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
GEP201606551B (en) | 2010-11-24 | 2016-10-10 | Novamedica Llc | Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging |
WO2015063669A1 (fr) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables |
CA3231766A1 (fr) * | 2021-09-22 | 2023-03-30 | Elizabeth W. JEFFORDS | Methodes de traitement de maladies inflammatoires oculaires |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
DK0416950T3 (da) * | 1989-09-08 | 1993-10-11 | Glaxo Group Ltd | Medikamenter |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
JP3573213B2 (ja) * | 1995-04-14 | 2004-10-06 | グラクソ、ウェルカム、インコーポレーテッド | ベクロメタゾンジプロピオネート用計量投与用吸入器 |
-
1998
- 1998-03-12 JP JP54063398A patent/JP2002504091A/ja active Pending
- 1998-03-12 NZ NZ337769A patent/NZ337769A/xx unknown
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/ko not_active Application Discontinuation
- 1998-03-12 SI SI9820032A patent/SI20110A/sl unknown
- 1998-03-12 DE DE0998300T patent/DE998300T1/de active Pending
- 1998-03-12 SK SK1221-99A patent/SK122199A3/sk unknown
- 1998-03-12 ES ES98912929T patent/ES2146192T1/es active Pending
- 1998-03-12 PL PL98336464A patent/PL336464A1/xx unknown
- 1998-03-12 CA CA002282845A patent/CA2282845A1/fr not_active Abandoned
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/xx unknown
- 1998-03-12 IL IL13181598A patent/IL131815A0/xx unknown
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/hu unknown
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 EP EP98912929A patent/EP0998300A1/fr not_active Withdrawn
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/fr not_active Application Discontinuation
- 1998-03-12 CN CN98805124A patent/CN1269722A/zh active Pending
- 1998-03-12 ID IDW991185A patent/ID22975A/id unknown
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/pt not_active IP Right Cessation
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/no unknown
- 1999-10-13 BG BG103808A patent/BG103808A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0104439A2 (hu) | 2002-04-29 |
AU6760498A (en) | 1998-10-12 |
WO1998041232A3 (fr) | 2000-10-05 |
SI20110A (sl) | 2000-06-30 |
TR199902615T2 (xx) | 2000-03-21 |
EP0998300A1 (fr) | 2000-05-10 |
JP2002504091A (ja) | 2002-02-05 |
ES2146192T1 (es) | 2000-08-01 |
NO994506L (no) | 1999-11-17 |
CA2282845A1 (fr) | 1998-09-24 |
PL336464A1 (en) | 2000-06-19 |
CN1269722A (zh) | 2000-10-11 |
SK122199A3 (en) | 2000-12-11 |
IL131815A0 (en) | 2001-03-19 |
KR20000076420A (ko) | 2000-12-26 |
ID22975A (id) | 1999-12-23 |
AU734756B2 (en) | 2001-06-21 |
NZ337769A (en) | 2002-09-27 |
BG103808A (en) | 2000-07-31 |
HUP0104439A3 (en) | 2002-08-28 |
NO994506D0 (no) | 1999-09-17 |
WO1998041232A2 (fr) | 1998-09-24 |
DE998300T1 (de) | 2001-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9810409A (pt) | Métodos e composições para a modulação de responsividade a corticosteróides | |
BR9714415A (pt) | Heterociclos contendo nitrogênio substituìdo como inibidores de proteìnas quinase p38 | |
BR9911786A (pt) | Inibidores heterocìclicos de p38 | |
DE69830404D1 (de) | P38-inhibitoren | |
BR0206985A (pt) | Anticorpos modificados e métodos de uso | |
TR200001312T2 (tr) | Benzotiyazol protein tirozin kinaz önleyicileri. | |
DE69724451D1 (de) | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen | |
BR9807577A (pt) | Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição | |
CA2339253A1 (fr) | Inhibiteurs de p38 | |
WO1999064059A3 (fr) | Utilisation de la secretine pour le traitement de l'autisme et d'autres troubles du comportement, troubles neurologiques ou immunologiques | |
NO963280L (no) | Anvendelse av anti-TNF antistoffer som legemidler i behandling av sykdommer som involverer forhöyede interleukin-6 serumnivåer | |
ES2136624T3 (es) | Implante biocompatible para regular la ovulacion en yeguas. | |
ES2102007T3 (es) | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. | |
WO2001019373A3 (fr) | Procedes et compositions permettant de moduler la sensibilite aux corticosteroides | |
BR9812134A (pt) | Composição farmacêutica para tratamento de dismenorréia e parto prematuro | |
NO960630L (no) | Heterocykler anvendelige som neurokinin antagonister | |
CA2274596A1 (fr) | Compositions et procedes servant a ameliorer le fonctionnement gastro-intestinal | |
FI972703A (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
BR0015416A (pt) | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos | |
BR9811780A (pt) | Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente | |
MX9704037A (es) | 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos. | |
EE05213B1 (et) | Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon | |
BR9914848A (pt) | Composição e processo para o tratamento de distúrbios da retina externa | |
HUT71331A (en) | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy | |
ATE275968T1 (de) | Mitteln zur behandlung von auto-immun krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007. |